Yazar "Kalay, Nihat" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Clinical outcome of B2/C type isolated proximal LAD disease treated with drug-eluting stents
    (Aves Yayincilik, 2011) Cicek, Davran; Pekdemir, Hasan; Kalay, Nihat; Muderrisoglu, Haldun
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Efficacy of Sirolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in an Unselected Population With Coronary Artery Disease: 24-Month Outcomes of Patients in a Prospective Non-randomized Registry in Southern Turkey
    (Ivyspring Int Publ, 2010) Cicek, Davran; Pekdemir, Hasan; Kalay, Nihat; Binici, Sueleyman; Altay, Hakan; Muderrisoglu, Haldun
    Background: The efficacy of drug-eluting stents has been shown in randomized trials, but some controversy exists regarding which stent sirolimus-eluting or paclitaxel-eluting is more effective in unselected Turkish patients. Therefore, we investigated the clinical outcomes of patients who were treated with one type of these drug-eluting stents in the real world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the sirolimus- or the paclitaxel-eluting stent. The follow-up period after stent implantation was approximately 24 months. The primary end point was a major cardiac event, and the secondary end point was stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 204 patients were treated with either the sirolimus-eluting stent (n = 103) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up, patients who received the paclitaxel-eluting stent showed significantly higher rates of non-Q-wave myocardial infarction (1.9% vs 5.9%; P: .002), target vessel revascularization (1.9% vs 4.9%; P: .002), coronary artery bypass graft surgery (1.9% vs 6.9%; P: .001), and late stent thrombosis (1.9% vs 3.9%, P: .002). Conclusions: Patients who received the sirolimus- eluting stent showed better clinical outcomes compared with those who had the paclitaxel-eluting-stent.
  • Küçük Resim Yok
    Öğe
    High-performance classification of STEMI and NSTEMI by automatic feature selection from ECG signals: a triple approach
    (Springer London Ltd, 2025) Latifoglu, Fatma; Icer, Semra; Guven, Aysegul; Zhusupova, Aigul; Avsarogullari, Omer Levent; Kelesoglu, Saban; Kalay, Nihat
    Acute Myocardial Infarction (AMI) remains a major health problem globally despite advances in diagnosis and treatment. Although electrocardiography (ECG) is a popular diagnostic tool, it can be difficult to interpret due to signal variability and pathology-related changes. This study proposes a triple approach to classify Healthy Controls (HC), ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) by applying the triple method to 12-lead ECG signals. The proposed method includes automatic feature and ECG derivation selection using Particle Swarm Optimisation (PSO), Least Absolute Shrinkage and Selection Operator (LASSO) and Linear Regression (LR) and signal decomposition using Variational Mode Decomposition (VMD). Classification is performed using machine learning algorithms such as Artificial Neural Network (ANN), K-nearest neighbours (KNN), Support Vector Machine (SVM) and Linear Discriminant Analysis (LDA). The proposed method is evaluated using both the original clinical dataset and the PTB-XL database. As a result of the evaluation, high classification performance was achieved for both the clinical dataset (Accuracy: 100%) and the open-source PTB-XL dataset (Accuracy: 99.60%). The results obtained in this study demonstrate the potential for fast and reliable diagnosis. The proposed work contributes to addressing the challenge of distinguishing between STEMI and NSTEMI, which is crucial for the treatment of AMI patients.
  • Küçük Resim Yok
    Öğe
    TWO-YEAR OUTCOME OF TURKISH PATIENTS TREATED WITH ZOTAROLIMUS VERSUS PACLITAXEL ELUTING STENTS IN AN UNSELECTED POPULATION WITH CORONARY ARTERY DISEASE
    (Karger, 2010) Cicek, Davran; Pekdemir, Hasan; Kalay, Nihat; Binici, Suleyman; Altay, Hakan; Muderrisoglu, Haldun
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
    (Ivyspring Int Publ, 2011) Cicek, Davran; Pekdemir, Hasan; Haberal, Cevahir; Kalay, Nihat; Binici, Suleyman; Altay, Hakan; Muderrisoglu, Haldun
    Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel- eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population.